Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-Deficient mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 4, 2015, Pages 948-959

  Chen, Yuanli ^a,b   Duan, Yajun ^a,b   Yang, Xiaoxiao ^a   Sun, Lei ^a   Liu, Mengyang ^a   Wang, Qixue ^a   Ma, Xingzhe ^a   Zhang, Wenwen ^a   Li, Xiaoju ^a   Hu, Wenquan ^c   Miao, Robert Q ^c   Xiang, Rong ^b   Hajjar, David P ^d   Han, Jihong ^a,b  

^a NANKAI UNIVERSITY   (China)

^b Collaborative Innovation Center of Biotherapy ^*  (China)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

atherosclerosis; extracellular signal regulated map kinases; foam cells; hypertriglyceridemia; lipogenesis; liver X receptor

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ABC TRANSPORTER A1; LIVER X RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; 1,3 BUTADIENE DERIVATIVE; APOLIPOPROTEIN E; CHOLESTEROL; FLUORINATED HYDROCARBON; MAPK1 PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRILE; ORPHAN NUCLEAR RECEPTOR; PROTEIN KINASE INHIBITOR; SULFONAMIDE; TO-901317;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; DRUG POTENTIATION; FATTY ACID OXIDATION; FATTY LIVER; FEMALE; HYPERTRIGLYCERIDEMIA; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; AORTIC DISEASES; C57BL MOUSE; CHEMICALLY INDUCED; DEFICIENCY; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; ENZYMOLOGY; FOAM CELL; GENETICS; HEPG2 CELL LINE; HUMAN; KNOCKOUT MOUSE; LIVER; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; AORTA; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BUTADIENES; CHOLESTEROL; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FATTY LIVER; FEMALE; FOAM CELLS; HEP G2 CELLS; HUMANS; HYDROCARBONS, FLUORINATED; HYPERTRIGLYCERIDEMIA; LIVER; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NITRILES; ORPHAN NUCLEAR RECEPTORS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84930249965     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.305116     Document Type: Article

References (39)

1. Mikhailidis DP, Athirst VG. Dyslipidaemia in 2013: new statin guidelines and promising novel therapeutics. Nat Rev Cardiol. 2014;11:72-74. doi: 10.1038/nrcardio.2013.209.
2. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045-2051. doi: 10.1161/ATVBAHA.108.179705.
3. Wang N, Tall AR. Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 2003;23:1178-1184. doi: 10.1161/01.ATV.0000075912.83860.26.
4. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denèfle P, Assmann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet. 1999;22:352-355. doi: 10.1038/11921.
5. Singaraja RR, Fievet C, Castro G, James ER, Hennuyer N, Clee SM, Bissada N, Choy JC, Fruchart JC, McManus BM, Staels B, Hayden MR. Increased ABCA1 activity protects against atherosclerosis. J Clin Invest. 2002;110:35-42. doi: 10.1172/JCI15748.
6. Calkin AC, Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol. 2012;13:213-224. doi: 10.1038/nrm3312.
7. Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A. 2002;99:7604-7609. doi: 10.1073/pnas.112059299.
8. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000;14:2819-2830.
9. Terasaka N, Hiroshima A, Koieyama T, Ubukata N, Morikawa Y, Nakai D, Inaba T. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 2003;536:6-11.
10. Chisholm JW, Hong J, Mills SA, Lawn RM. The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J Lipid Res. 2003;44:2039-2048. doi: 10.1194/jlr.M300135-JLR200.
11. Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol. 2000;16:459-481. doi: 10.1146/annurev.cellbio.16.1.459.
12. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4:937-947. doi: 10.1038/nrc1503.
13. Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep. 2011;13:544-552. doi: 10.1007/s11886-011-0220-3.
14. Sparks JD, Sparks CE, Adeli K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2012;32:2104-2112. doi: 10.1161/ATVBAHA.111.241463.
15. Kidani Y, Bensinger SJ. Liver X receptor and peroxisome proliferator-activated receptor as integrators of lipid homeostasis and immunity. Immunol Rev. 2012;249:72-83. doi: 10.1111/j.1600-065X.2012.01153.x.
16. Zhou X, Yin Z, Guo X, Hajjar DP, Han J. Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol efflux. J Biol Chem. 2010;285:6316-6326. doi: 10.1074/jbc.M109.073601.
17. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B. Role of LXRs in control of lipogenesis. Genes Dev. 2000;14:2831-2838.
18. Hwang SL, Lu Y, Li X, Kim YD, Cho YS, Jahng Y, Son JK, Lee YJ, Kang W, Taketomi Y, Murakami M, Moon TC, Chang HW. ERK1/2 antagonize AMPK-dependent regulation of FcepsilonRI-mediated mast cell activation and anaphylaxis. J Allergy Clin Immunol. 2014;134(3):714-721.e7.
19. Zheng C, Azcutia V, Aikawa E, Figueiredo JL, Croce K, Sonoki H, Sacks FM, Luscinskas FW, Aikawa M. Statins suppress apolipoprotein CIIIinduced vascular endothelial cell activation and monocyte adhesion. Eur Heart J. 2013;34:615-624. doi: 10.1093/eurheartj/ehs271.
20. Cases S, Smith SJ, Zheng YW, Myers HM, Lear SR, Sande E, Novak S, Collins C, Welch CB, Lusis AJ, Erickson SK, Farese RV Jr. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci U S A. 1998;95:13018-13023.
21. Zimmermann R, Strauss JG, Haemmerle G, Schoiswohl G, Birner-Gruenberger R, Riederer M, Lass A, Neuberger G, Eisenhaber F, Hermetter A, Zechner R. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science. 2004;306:1383-1386. doi: 10.1126/ science.1100747.
22. Quiroga AD, Lehner R. Liver triacylglycerol lipases. Biochim Biophys Acta. 2012;1821:762-769. doi: 10.1016/j.bbalip.2011.09.007.
23. Lass A, Zimmermann R, Haemmerle G, Riederer M, Schoiswohl G, Schweiger M, Kienesberger P, Strauss JG, Gorkiewicz G, Zechner R. Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman syndrome. Cell Metab. 2006;3:309-319. doi: 10.1016/j.cmet.2006.03.005.
24. Zandbergen F, Plutzky J. PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta. 2007;1771:972-982. doi: 10.1016/j. bbalip.2007.04.021.
25. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288-1295. doi: 10.1038/nm788.
26. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435. doi: 10.1056/NEJMoa050461.
27. Loren J, Huang Z, Laffitte BA, Molteni V. Liver X receptor modulators: A review of recently patented compounds (2009-2012). Expert Opin Ther Pat 2013;23(10):1317-1335.
28. Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N Engl J Med. 1980;302:1383-1389. doi: 10.1056/ NEJM198006193022503.
29. Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O'Connell JR, Shuldiner AR. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322:1702-1705. doi: 10.1126/science.1161524.
30. Kawakami A, Osaka M, Tani M, Azuma H, Sacks FM, Shimokado K, Yoshida M. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation. 2008;118:731-742. doi: 10.1161/ CIRCULATIONAHA.108.784785.
31. Carey VJ, Bishop L, Laranjo N, Harshfield BJ, Kwiat C, Sacks FM. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol. 2010;106:757-763. doi: 10.1016/j.amjcard.2010.05.002.
32. Zhang Y, Breevoort SR, Angdisen J, Fu M, Schmidt DR, Holmstrom SR, Kliewer SA, Mangelsdorf DJ, Schulman IG. Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. J Clin Invest. 2012;122:1688-1699. doi: 10.1172/JCI59817.
33. Gao M, Liu D. Resveratrol suppresses T0901317-induced hepatic fat accumulation in mice. AAPS J. 2013;15:744-752. doi: 10.1208/ s12248-013-9473-7.
34. Escolà-Gil JC, Julve J, Llaverias G, Urpi-Sarda M, Silvennoinen R, Lee-Rueckert M, Andres-Lacueva C, Blanco-Vaca F. Resveratrol administration or SIRT1 overexpression does not increase LXR signaling and macrophage-to-feces reverse cholesterol transport in vivo. Transl Res. 2013;161:110-117. doi: 10.1016/j.trsl.2012.10.008.
35. Breevoort SR, Angdisen J, Schulman IG. Macrophage-independent regulation of reverse cholesterol transport by liver X receptors. Arterioscler Thromb Vasc Biol. 2014;34:1650-1660. doi: 10.1161/ ATVBAHA.114.303383.
36. Zhang Y, Breevoort SR, Angdisen J, Fu M, Schmidt DR, Holmstrom SR, Kliewer SA, Mangelsdorf DJ, Schulman IG. Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. J Clin Invest. 2012;122:1688-1699. doi: 10.1172/ JCI59817.
37. Kappus MS, Murphy AJ, Abramowicz S, Ntonga V, Welch CL, Tall AR, Westerterp M. Activation of liver X receptor decreases atherosclerosis in Ldlr-/- mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells. Arterioscler Thromb Vasc Biol. 2014;34:279-284. doi: 10.1161/ATVBAHA.113.302781.
38. Levin N, Bischoff ED, Daige CL, Thomas D, Vu CT, Heyman RA, Tangirala RK, Schulman IG. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler Thromb Vasc Biol. 2005;25:135-142. doi: 10.1161/01.ATV.0000150044.84012.68.
39. Giannarelli C, Cimmino G, Connolly TM, Ibanez B, Ruiz JM, Alique M, Zafar MU, Fuster V, Feuerstein G, Badimon JJ. Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis. Eur Heart J. 2012;33:264-273. doi: 10.1093/eurheartj/ehr136.